Nurix bexobrutideg shows 80.9% ORR in CLL, 84.2% in WM; pivotal trials on track for 2025

Nurix Therapeutics, Inc.

ORR 80.9% in CLL/SLL (n=47 evaluable); median time to first response 1.9 months; one complete response after >2 years.
ORR 84.2% in WM (n=19 evaluable); included 10.5% VGPR, 57.9% PR; IgM reductions >90% in three patients.
Well tolerated across 50-600 mg doses; common AEs low-grade purpura/contusion (45.8%), neutropenia (29.2%); no new atrial fibrillation.
Patients heavily pretreated: median 4 prior lines, 97.9% prior BTKi, 83.3% prior BCL2i; responses seen regardless of baseline mutations or CNS involvement.
Nurix on track to initiate pivotal trials of bexobrutideg in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.